For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...

For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended an update to Novo ...

Novo Nordisk receives a positive opinion from the CHMP for a label update of Wegovy to reflect reduced heart failure symptoms ...

Tectonic Therapeutics Inc. (TECX) announced favorable Phase 1a topline data for its lead asset, TX45, a long-acting, potentially ...

Bagsværd, Denmark Saturday, September 21, 2024, 15:00 Hrs [IST] ...

The trial results indicated minimal adverse events and no evidence of immune-mediated clearance following TX45 treatment.

TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the ...

Quotient Sciences, Vasa Therapeutics dose first human subjects with VS-041, a novel therapy for heart failure with preserved ejection fraction: Nottingham, UK Monday, September 16 ...

The European Medicines Agency’s (EMA) advisory committee the CHMP has adopted a positive opinion for a label update of Danish ...

For patients with HFPEF and other underlying comorbidities, such as diabetes or coronary artery disease, treatment with an ACE inhibitor is nonetheless beneficial. The theoretical benefits of ACE ...

"We have four pillars of guideline-directed medical therapy in HFrEF, but only SGLT2 inhibitors as a treatment option for HFmrEF/HFpEF," he said. "Given that finerenone was beneficial in patients ...